Latest on Ultrasound Renal Denervation
Published: 22 June 2022
-
Views:
7475
-
Likes:
7
-
Views:
7475
-
Likes:
7
-
19m 35s -
11m 41sPart 3 | Session 2 "Ultrasound RDN - Reviewing the Latest Clinical Results" : Joost Daemen -
28m 37sPart 3 | Session 3 "How to build Interventional HTN Therapy/Practice": Joachim Weil
-
5m 12sPart 4 | Session 1 RADIANCE II Pivotal Trial -
1h 20s
-
5m 10s -
4m 44s -
16m 20sPart 5 | Session 3 ACC 2021 – RADIANCE-HTN TRIO Trial Results with Ajay Kirtane -
5m 47sPart 5 | Session 4 EuroPCR 2020 – Crossover Results From the RADIANCE-HTN SOLO Trial
-
1h 4m 58sPart 7 | Session 1 ACC 2022 Symposium -
59m 32sPart 7 | Session 2 TCT 2021 Symposium
-
4m 2sPart 1 | Session 1 The Science of Ultrasound Renal Denervation: Introduction Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
-
9m 18sPart 1 | Session 2 Ultrasound Technology – Its Development and Unique Characteristics: Andy Wu Andrew Wu
-
15m 10sPart 1 | Session 3 Ultrasound Renal Denervation Preclinical Evidence: Dr Michael Joner Michael Joner
-
18m 36sPart 1 | Session 4 RDN Procedure with Ultrasound Technology: Prof Felix Mahfoud Felix Mahfoud
-
10m 14sPart 1 | Session 5 Panel Discussion: All Philipp Lurz, Michael Joner, Felix Mahfoud, Andrew Wu
-
15m 15sPart 2 | Session 1 The Paradise uRDN System: Dr Andrew Sharp Andrew SP Sharp
-
9m 57sPart 2 | Session 2 uRDN Clinical Evidence - What does this mean for the field?: Prof Felix Mahfoud Felix Mahfoud
Overview
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.
The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
What you will learn:
- How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
- The clinical evidence supporting uRDN and its implications for the field of hypertension
- The process for building a uRDN centre and therapy network
This page is designed for:
- Interventional cardiologists
- General cardiologists
- Hypertension specialists
- Nephrologists
- Interventional radiologists
More from this programme
Part 1
The Science of uRDN
Part 2
The Evidence for uRDN
Part 3
From Proof to Practice – Treating Hypertension With uRDN
Part 4
RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension
Part 5
Results From the Latest Clinical Trials
Part 6
Patient Perspective & Provider Referral Development
Part 7
Discussion With Experts
| 2 sessions | |
| ACC 2022 Symposium | Watch now |
| TCT 2021 Symposium | Watch now |
Faculty Biographies
Roland E Schmieder
Professor of Internal Medicine, Nephrology and Hypertension, Head of the Clinical Research Centre and Vice Chair of the Department of Nephrology and Hypertension
Roland E Schmieder is a Professor of Internal Medicine, Nephrology and Hypertension, Head of the Clinical Research Centre and Vice Chair of the Department of Nephrology and Hypertension at the University Hospital Erlangen, Germany. He also directs the Institute of Preventative Medicine at the University Erlangen-Nuremberg and the Community Hospital Nuremberg. Roland is a member of numerous professional societies and committees, and is a Fellow of the American College of Physicians (ACP) and the American College of Cardiology (ACC). He is on the international Editorial Board of the American Journal of Hypertension, the Journal of Human Hypertension and the Journal of Nephrology, among other scientific journals. Professor Schmieder received his post-graduate medical training in nephrology, cardiology and hypertension at the University Hospital of Bonn, and then at the Alton Ochsner Foundation, New Orleans. He graduated in medicine from the…